PE20220573A1 - Inhibidores de fgfr y metodos de uso de los mismos - Google Patents
Inhibidores de fgfr y metodos de uso de los mismosInfo
- Publication number
- PE20220573A1 PE20220573A1 PE2021001878A PE2021001878A PE20220573A1 PE 20220573 A1 PE20220573 A1 PE 20220573A1 PE 2021001878 A PE2021001878 A PE 2021001878A PE 2021001878 A PE2021001878 A PE 2021001878A PE 20220573 A1 PE20220573 A1 PE 20220573A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- formula
- fgfr
- membered
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962846991P | 2019-05-13 | 2019-05-13 | |
| US202062993957P | 2020-03-24 | 2020-03-24 | |
| US202063011469P | 2020-04-17 | 2020-04-17 | |
| PCT/US2020/032474 WO2020231990A1 (en) | 2019-05-13 | 2020-05-12 | Fgfr inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220573A1 true PE20220573A1 (es) | 2022-04-20 |
Family
ID=73289291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001878A PE20220573A1 (es) | 2019-05-13 | 2020-05-12 | Inhibidores de fgfr y metodos de uso de los mismos |
Country Status (17)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3065954T3 (en) * | 2019-05-13 | 2026-05-08 | Relay Therapeutics Inc | Fgfr inhibitors and methods of use thereof |
| JP2021017595A (ja) * | 2019-07-18 | 2021-02-15 | 花王株式会社 | アニオン変性セルロース |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| AU2021263914B2 (en) | 2020-04-29 | 2026-07-23 | D.E. Shaw Research, Llc | PI3K-α inhibitors and methods of use thereof |
| TWI924727B (zh) | 2020-11-18 | 2026-05-11 | 美商傳達治療有限公司 | Ｆｇｆｒ抑制劑及其製造及使用方法 |
| CN115160319B (zh) * | 2021-04-01 | 2023-12-26 | 西安新通药物研究股份有限公司 | 含1,3-苯并二氧戊环结构的化合物及其制备方法与用途 |
| TW202304889A (zh) * | 2021-04-03 | 2023-02-01 | 大陸商海南耀臻生物醫藥科技有限公司 | 作為fgfr抑制劑的雜環化合物及其應用 |
| WO2023011581A1 (zh) * | 2021-08-04 | 2023-02-09 | 江苏恒瑞医药股份有限公司 | 含氮杂环化合物、其制备方法及其在医药上的应用 |
| CA3231948A1 (en) * | 2021-09-23 | 2023-03-30 | Jingyu Hu | Fgfr inhibitors and methods of use thereof |
| WO2023104035A1 (zh) * | 2021-12-06 | 2023-06-15 | 英矽智能科技(上海)有限公司 | 取代的单环或双环杂环化合物，其制法与医药上的用途 |
| WO2023151560A1 (en) * | 2022-02-08 | 2023-08-17 | Etern Biopharma (Shanghai) Co., Ltd. | Bicyclic heteroaryl compounds and uses thereof |
| US20260152503A1 (en) * | 2022-03-31 | 2026-06-04 | Acerand Therapeutics (Hong Kong) Limited | Spirobicyclic compounds |
| WO2023202625A1 (zh) * | 2022-04-20 | 2023-10-26 | 深圳福沃药业有限公司 | Fgfr2抑制剂及使用方法 |
| US20250313524A1 (en) * | 2022-05-10 | 2025-10-09 | Relay Therapeutics, Inc. | Pi3k-alpha inhibitors and methods of use thereof |
| JP2025523588A (ja) * | 2022-06-29 | 2025-07-23 | インシリコ メディスン アイピー リミテッド | Ｆｇｆｒ２及びｆｇｆｒ３の阻害剤並びにその使用 |
| CN119421872A (zh) * | 2022-06-29 | 2025-02-11 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| CN117402161A (zh) * | 2022-07-06 | 2024-01-16 | 上海科恩泰生物医药科技有限公司 | 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途 |
| CA3266687A1 (en) * | 2022-09-07 | 2024-03-14 | Eli Lilly And Company | PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR3 INHIBITORS FOR CANCER TREATMENT |
| CN120051471A (zh) * | 2022-10-18 | 2025-05-27 | 首药控股(北京)股份有限公司 | 一种新型杂环化合物 |
| CN115594682B (zh) * | 2022-10-26 | 2024-03-15 | 苏州浦合医药科技有限公司 | Fgfr2抑制剂 |
| WO2024109799A1 (zh) * | 2022-11-22 | 2024-05-30 | 西藏海思科制药有限公司 | 一种嘧啶衍生物及其在医药上的应用 |
| WO2024175121A1 (zh) * | 2023-02-24 | 2024-08-29 | 希格生科（深圳）有限公司 | α，β-不饱和酰胺类化合物及其应用 |
| TW202442224A (zh) * | 2023-03-20 | 2024-11-01 | 香港商英矽智能科技知識產權有限公司 | Fgfr2與fgfr3之抑制劑及其用途 |
| WO2024208315A1 (zh) * | 2023-04-07 | 2024-10-10 | 中国医药研究开发中心有限公司 | 芳香杂环类化合物及其制备方法和医药用途 |
| WO2024245193A1 (zh) * | 2023-05-26 | 2024-12-05 | 上海艾力斯医药科技股份有限公司 | 杂芳环类化合物、其药物组合物及其应用 |
| KR20260009912A (ko) | 2023-06-05 | 2026-01-20 | 캉바이다 (시추안) 바이오테크놀로지 씨오. 엘티디. | 피롤로피리미딘 유도체 및 의약물 제조에서 이의 용도 |
| WO2025067484A1 (en) * | 2023-09-28 | 2025-04-03 | Acerand Therapeutics (Hong Kong) Limited | Crystal forms and salts of spirobicyclic compound |
| CN117343068B (zh) * | 2023-09-28 | 2026-04-28 | 上海相辉医药科技有限公司 | 一种FGFR2抑制剂Lirafugratinib(RLY-4008)的制备方法 |
| KR20260115897A (ko) * | 2023-11-17 | 2026-07-27 | 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 | 질소 함유 헤테로아릴 유도체, 이의 제조 방법 및 의약학적 응용 |
| CN120230109A (zh) * | 2023-12-29 | 2025-07-01 | 广州科恩泰生物医药科技有限公司 | 一种亚砜亚胺类化合物的酸式盐的晶型及其制备方法和用途 |
| WO2025149021A1 (zh) * | 2024-01-10 | 2025-07-17 | 海思科医药集团股份有限公司 | 一种吡啶并吡咯衍生物及其在医药上的应用 |
| WO2025237312A1 (zh) * | 2024-05-15 | 2025-11-20 | 深圳福沃药业有限公司 | 一类含苯并异噁唑结构的高选择性fgfr2抑制剂及其制备方法和应用 |
| CN121270563A (zh) * | 2024-07-01 | 2026-01-06 | 北京鞍石生物科技股份有限公司 | 稠环化合物及其制备方法和应用 |
| WO2026119036A1 (zh) * | 2024-12-04 | 2026-06-11 | 康百达（四川）生物医药科技有限公司 | 一种吡咯并嘧啶衍生物的晶型及其制备方法 |
| CN120136834B (zh) * | 2025-02-13 | 2026-02-03 | 浙江工业大学 | 一种手性吡喃环化合物及其合成方法和应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB119249A (en) | 1917-06-09 | 1918-10-03 | Du Pont | Process of Producing Alcohols. |
| US2319070A (en) | 1938-03-31 | 1943-05-11 | Eastman Kodak Co | Manufacture of unsaturated aliphatic acids and anhydrides |
| ATE202109T1 (de) | 1993-03-12 | 2001-06-15 | Upjohn Co | Kristallines ceftiofur (freie säure) |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| PT938486E (pt) * | 1996-08-23 | 2008-03-27 | Novartis Ag | Pirrolopirimidinas substituídas e processos para a sua preparação |
| BR9808281A (pt) | 1997-03-19 | 2000-05-16 | Basf Ag | Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto |
| MX9909255A (en) | 1997-04-09 | 2000-06-01 | Commw Scient Ind Res Org | Process for covalently coupling organic compounds utilizing diboron derivatives for preparation of an aryl boronic acid |
| AUPQ441499A0 (en) | 1999-12-02 | 2000-01-06 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound |
| GB0031080D0 (en) | 2000-12-20 | 2001-01-31 | Novartis Ag | Organic compounds |
| AUPR548601A0 (en) * | 2001-06-06 | 2001-06-28 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyrazinecompound and pharmaceutical use thereof |
| US7323469B2 (en) | 2001-08-07 | 2008-01-29 | Novartis Ag | 7H-pyrrolo[2,3-d]pyrimidine derivatives |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| AU2002333524A1 (en) | 2001-09-11 | 2003-03-24 | Glaxosmithkline K.K. | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| UA80295C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| CN1871240B (zh) | 2003-08-26 | 2012-11-07 | 帝人制药株式会社 | 吡咯并嘧啶酮衍生物 |
| JP2007510136A (ja) | 2003-10-06 | 2007-04-19 | ソルヴィーアス アクチェンゲゼルシャフト | 分子状固体の結晶形態を並行検出する方法 |
| UY28931A1 (es) * | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| JP2008505084A (ja) | 2004-06-29 | 2008-02-21 | アムゲン インコーポレイティッド | フラノピリミジン |
| MXPA06015237A (es) | 2004-06-29 | 2007-12-10 | Amgen Inc | Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck. |
| DE102005061170A1 (de) * | 2005-12-21 | 2007-07-05 | Bayer Healthcare Ag | Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung |
| US8765754B2 (en) | 2009-04-29 | 2014-07-01 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| CN102286048A (zh) * | 2011-06-24 | 2011-12-21 | 吉林大学 | 4-氨基-6-(3-(3-溴苯基)苯基)-5-氰基-7-(β-L-呋喃木糖)吡咯并[2, 3-d]嘧啶、同类衍生物及用于制备抗肿瘤药物 |
| WO2013078254A1 (en) | 2011-11-22 | 2013-05-30 | Array Biopharma Inc. | Bicyclic heteroaryl derivatives as kinase inhibitors |
| EP2788000B1 (en) | 2011-12-06 | 2018-05-30 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| AU2013210403B2 (en) * | 2012-01-19 | 2016-01-14 | Taiho Pharmaceutical Co., Ltd. | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| DK3269370T3 (da) * | 2016-02-23 | 2020-04-06 | Taiho Pharmaceutical Co Ltd | Hidtil ukendt kondenseret pyrimidinforbindelse eller salt deraf |
| CN110022900A (zh) | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 |
| EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| ES3065954T3 (en) | 2019-05-13 | 2026-05-08 | Relay Therapeutics Inc | Fgfr inhibitors and methods of use thereof |
| CN116947885B (zh) | 2019-09-20 | 2026-01-23 | 上海济煜医药科技股份有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
| EP4053120A4 (en) | 2019-10-28 | 2023-11-01 | Nippon Soda Co., Ltd. | COMPOUND 2,6-DIOXO-3,6-DIHYDROPYRIMIDINE, AGRICULTURAL AND HORTICULTURAL BACTERICIDE, NEMATICIDE AND MEDICAL AND VETERINARY ANTIFUNGAL AGENT |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| KR102980664B1 (ko) | 2020-04-17 | 2026-06-19 | 신젠타 크롭 프로텍션 아게 | 제초 화합물 |
| TWI924727B (zh) | 2020-11-18 | 2026-05-11 | 美商傳達治療有限公司 | Ｆｇｆｒ抑制劑及其製造及使用方法 |
-
2020
- 2020-05-12 ES ES23210430T patent/ES3065954T3/es active Active
- 2020-05-12 US US17/595,257 patent/US12522605B2/en active Active
- 2020-05-12 MX MX2021013146A patent/MX428348B/es unknown
- 2020-05-12 JP JP2021566480A patent/JP7527309B2/ja active Active
- 2020-05-12 BR BR112021022457A patent/BR112021022457A2/pt unknown
- 2020-05-12 PH PH1/2021/552862A patent/PH12021552862A1/en unknown
- 2020-05-12 CN CN202411852620.8A patent/CN119874707A/zh active Pending
- 2020-05-12 AU AU2020274083A patent/AU2020274083B9/en active Active
- 2020-05-12 KR KR1020217040628A patent/KR102923990B1/ko active Active
- 2020-05-12 KR KR1020267003072A patent/KR20260030158A/ko active Pending
- 2020-05-12 SG SG11202111327XA patent/SG11202111327XA/en unknown
- 2020-05-12 WO PCT/US2020/032474 patent/WO2020231990A1/en not_active Ceased
- 2020-05-12 CN CN202080035916.4A patent/CN114126620B/zh active Active
- 2020-05-12 PE PE2021001878A patent/PE20220573A1/es unknown
- 2020-05-12 CA CA3137458A patent/CA3137458A1/en active Pending
- 2020-05-12 EP EP23210430.7A patent/EP4306529B1/en active Active
- 2020-05-12 EP EP20805444.5A patent/EP3968999B1/en active Active
- 2020-05-12 IL IL287940A patent/IL287940B2/en unknown
- 2020-05-12 ES ES20805444T patent/ES2974985T3/es active Active
- 2020-05-13 TW TW109115853A patent/TWI855070B/zh active
- 2020-05-13 TW TW113133749A patent/TWI921912B/zh active
-
2021
- 2021-11-03 CL CL2021002882A patent/CL2021002882A1/es unknown
-
2023
- 2023-01-31 US US18/162,127 patent/US11780845B2/en active Active
-
2024
- 2024-07-23 JP JP2024117746A patent/JP2024156729A/ja active Pending
-
2025
- 2025-04-08 AU AU2025202494A patent/AU2025202494A1/en active Pending
- 2025-09-29 IL IL323675A patent/IL323675A/en unknown
- 2025-11-25 US US19/401,237 patent/US20260138983A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22029777A (es) | Heterociclos bic?clicos como inhibidores de fgfr | |
| PE20170925A1 (es) | Composiciones y metodos para el tratamiento de trastornos del snc | |
| MX2019001223A (es) | Moduladores de receptores de quimioquina y usos de los mismos. | |
| MX2021013197A (es) | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. | |
| PE20180462A1 (es) | Moduladores cot y metodos de uso de los mismos | |
| PE20180117A1 (es) | Inhibidores de indolamina-2,3-dioxigenasa para el tratamiento de cancer | |
| CO2021001217A2 (es) | Inhibidores tipo indol y azaindol de enzimas pad | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| CL2020002698A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| CO2019002239A2 (es) | Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados | |
| EA201991598A1 (ru) | СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR) | |
| AR099023A1 (es) | Pirazolil-heteroarilamidas como agentes plaguicidas | |
| AR106799A1 (es) | Inhibidores éster de acc y usos de los mismos | |
| PE20151594A1 (es) | Inhibidores de indolamina 2-3 dioxigenasa | |
| AR062696A1 (es) | N-(1-hetaril- piperidin -4-il)- (het) arilamidas como moduladores del receptor ep2. | |
| AR096052A1 (es) | Compuestos y sus usos para la modulación de hemoglobina | |
| CL2019002112A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr). | |
| PE20200342A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
| EA201991599A1 (ru) | СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR) | |
| AR129281A1 (es) | INHIBIDORES DE PI3Ka Y MÉTODOS DE USO DE LOS MISMOS | |
| PE20180687A1 (es) | Reactivos quirales para la preparacion de oligomeros homogeneos | |
| MX2022004565A (es) | Tienopirimidonas como inhibidores de trpa1. | |
| EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 | |
| AR096040A1 (es) | Compuestos sustituidos y condensados de pirimidina como inhibidores de pde4b |